Exact Sciences is acquiring U.S. rights to Freenome’s colorectal cancer liquid biopsy test with a $75 million upfront payment, positioning to challenge Guardant Health in the expanding early cancer detection market. The partnership aims to leverage Freenome’s advanced blood-based screening technology to improve colorectal cancer diagnosis. This move reflects continued industry consolidation and aggressive competition in non-invasive multi-cancer screening diagnostics.